

HTAi Regional Meeting

Hosted by HTAi & the Azerbaijan Ministry of Health

October 17-18, 2022 · Azerbaijan University



HTA Training Agenda

This 2-day training course provides an introduction to Health Technology Assessment. The discussions on fundamental concepts and trends will enhance the understanding of HTA and offer a foundation for future skill development. The training program will focus on adapting HTA approaches to various technologies and offer insight into HTA practice and applications in various contexts.

Facilitators: Cliff Goodman, Krzysztof Landa, Wim Goettsch

Monday, October 17

Facilitator: Cliff Goodman

09:00 – 09:10 **Welcome and Introduction**

09:10 – 10:30 **Introduction to HTA**

- What is HTA, and its role in the health care system?
- Use of HTA
- HTA process
- *Discussion*

10:30 – 10:50 **Coffee Break and Networking**

10:50 – 12:00 **HTA methods**

- What are the properties and impacts assessed?
- Primary methods (RCTs, registries, surveillance, etc.)
- Secondary methods (systematic reviews, meta-analysis, modeling)
- *Discussion*

12:00 – 13:00 **Lunch**

13:00 – 14:10 **HTA methods (cont.)**

- Secondary methods (cont.)
- Evidence Appraisal
- Priority setting

Facilitator: Krzysztof Landa

14:10 – 16:15 **Essentials of drug and medical device reimbursement**

- Drug reimbursement system in Poland and other countries
- Basic principles of reimbursement and pricing decisions
- Application of HTA in marketing authorization and reimbursement
- *Question & Answer session*

Tuesday, October 18

Facilitator: Wim Goetsch

09:00-09:15 **Q & A session (recap from the previous day)**

09:15 – 10:30 **Essentials of Health Economics (HE)**

- Introduction to economic and financial analysis

10:30 – 10:50 **Coffee Break and Networking**

10:50 – 12:00 **HTA methods**

- How is HE positioned within HTA?
- HE evaluation in HTA reports
- *Break out Session: Work on a case study*

12:00 – 13:00 **Lunch**

Facilitator: Cliff Goodman

13:00 – 14:00 **Essentials of HTA methods**

- *Discussion*

14:00 – 16:00 **Other aspects of HTA**

- HTA in the lifecycle of the HT
- Multi-stakeholder approach to HTA
- Recent trends in HTA

About the Facilitators

Clifford Goodman, PhD

Clifford Goodman, PhD, is a Senior Vice President at The Lewin Group, a health care policy consulting firm based in Virginia, U.S. Lewin is an Optum company, a wholly owned subsidiary of UnitedHealth Group.

Dr. Goodman has more than 30 years of experience in health technology assessment, evidence-based health care, comparative effectiveness research, clinical practice guidelines, health economics, and studies pertaining to health care innovation, regulation, and payment. He directs projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. He has engaged in HTA training for many years.

Dr. Goodman served as Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC, 2009-12) for the U.S. Centers for Medicare and Medicaid Services. He served as President of the professional society, Health Technology Assessment international (HTAi, 2011-13), and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2022, he received the David Banta Distinguished Career Award in Health Technology Assessment from HTAi.

Dr. Goodman earned a PhD from The Wharton School of the University of Pennsylvania, a Master of Science from The Georgia Institute of Technology, and a Bachelor of Arts from Cornell University.

Krzysztof Łanda, MD

Krzysztof Łanda, M.D., the President of MedInvest Scanner Ltd., a company dealing with market access, pricing and reimbursement, due diligence and evaluation of innovativeness of health technologies. He used to work for DBSE and was a member of the international Dentons Pharmaceutical Law and Health Care team. Krzysztof was Deputy Minister of Health in 2015-2017 and was responsible for drug policy, reimbursement and prices of medical devices, mapping of health needs, investments in health care, prices of health services and the basic benefits package. Krzysztof was previously the CEO of HTA Audit, a company dealing with the quality assessment of HTA reports addressed to authorities and public institutions

and the President of the Watch Health Care Foundation. In 2010-2011 he was President of the Central & Eastern European Society of Technology Assessment in Health Care. In 2006-2007 was a Director of the Drug Policy Department in the Central Office of the National Health Fund. In 2004 Krzysztof was elected to the Board of Directors of Health Technology Assessment International (HTAi) where he remained until mid-2007. In 2010-2012 Krzysztof led capacity building in HTA in Ukraine, and in 2006-2008 in Serbia. He was a team leader of a World Bank project aimed at introducing EBHC principles in Serbia.

Wim Goettsch, PhD

Wim Goettsch, PhD, is currently Special Advisor HTA at the Dutch National Health Care Institute He was the Director of the EUnetHTA JA3 (2016-2021) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he also has a position as an Associate

Professor at Utrecht University (NL) where he is leading a new H2020 consortium with fifteen partners around Europe, called HTx on new methods for Health Technology Assessment for personalized medicine (2019-2024).